4D Molecular Therapeutics (FDMT)

• Market cap: $141M
• 1 day: -5.88%
• 5 days: -16.48%
• 1 month: -26.57%
• 3 months: -47.86%
• 6 months: -70.80%
• Year to date: -47.86%
• 1 year: -89.87%
• 5 years: -92.49%
• 10 years: -92.49%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

132% more call options, than puts

Call options by funds: $858K | Put options by funds: $370K

19% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 27

16% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 44

4% more funds holding

Funds holding: 139 [Q3] → 144 (+5) [Q4]

10.29% less ownership

Funds ownership: 111.65% [Q3] → 101.37% (-10.29%) [Q4]

58% less capital invested

Capital invested by funds: $628M [Q3] → $262M (-$366M) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 97% upside
• Avg. target: $29 843% upside
• High target: $40 1,216% upside

6 analyst ratings

• positive: 5 83%
• neutral: 0 0%
• negative: 1 17%

B of A Securities Tazeen Ahmad 26% 1-year accuracy 9 / 34 met price target	1,216% upside $40	Buy Maintained	10 Mar 2025
Chardan Capital Geulah Livshits 10% 1-year accuracy 6 / 58 met price target	821% upside $28	Buy Maintained	4 Mar 2025
RBC Capital Luca Issi 22% 1-year accuracy 12 / 55 met price target	1,051% upside $35	Outperform Maintained	3 Mar 2025
HC Wainwright & Co. Matthew Caufield 35% 1-year accuracy 22 / 63 met price target	1,084% upside $36	Buy Reiterated	3 Mar 2025
Morgan Stanley Judah Frommer 36% 1-year accuracy 4 / 11 met price target	97% upside $6	Underweight Maintained	13 Jan 2025